Zalicus Inc Com (NASDAQ:ZLCS)
CAPS Rating:
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
A biopharmaceutical company pioneering the new field of synergistic combination pharmaceuticals, with a portfolio of product candidates in phase 2 clinical development.
Recs
The potential for good news on there pain drug Synavive, could move the price of this stock up in the next several months which could make this a good trade.